v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Change in the Carrying Value of Equity Method Investment - Footnotes (Details) - Haleon [Member] - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 29, 2024
Jun. 30, 2024
Dec. 31, 2024
Oct. 31, 2024
Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]          
Pfizer share of Haleon investee capital transaction $ 46 $ (91) $ (44) [1],[2]    
Equity method investment, ownership percentage   23.00% 32.00% 15.00% 32.00%
[1] Included in Other (income)/deductions––net.
[2] Includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.